Retatrutide is a synthetic peptide and investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors [1], [2]
This innovation contests the conventional dependence on injectable formulations and has the potential to enhance patient acceptability and adherence
It helps signal fullness, supports insulin response, slows stomach emptying, and communicates with appetite centers in the brain
However, when it comes to pregnancy, the existing literature urges caution due to the limited data on the safety of GLP-1 medications during this crucial period
Nonclinical programs should include organ-system panels, cardiovascular telemetry where appropriate, and full pathology review to characterize off-target consequences of chronic ERR activation
In simple terms, retatrutide works by mimicking and enhancing signals that tell the brain when you are full, help regulate blood sugar, and influence how the body uses and stores energy